[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549583":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCvac cells to treat MM","EXPERIMENTAL",null,[13],"Biological: DC vaccines",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","DC vaccines","Antigen-presenting and immune modifying DCvacs to treat MM",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Lung-Ji Chang, ph.D","CONTACT","+86 0755-86573763","c@szgimi.org",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.0683,22.54554,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100549583","phase-1-engineered-dendritic-cell-vaccines-for-multiple-myeloma-100549583",false,"NCT06435910","Engineered Dendritic Cell Vaccines for Multiple Myeloma","Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients","Inclusion Criteria:\n\n* Male and female subjects with multiple myeloma or plasmacytoma\n* Very good partial or complete remission (CR) after prior combination therapies.\n* Expected survival \\> 12 weeks\n* Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal\n* Voluntary informed consent is given with willingness to continue follow up\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Uncontrolled active infection\n* HIV or active hepatitis B or hepatitis C infection\n* Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary","ALL","18 Years","80 Years",{"count":56,"type":57},10,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.",[63],"Multiple Myeloma or Plasmacytoma",[65,66,67],"MM","CAR T","DC vaccine","2026-06-18",{"date":70,"type":71},"2026-06-23","ACTUAL",{"date":73,"type":71},"2024-05-11",{"date":75,"type":57},"2027-12-31",{"name":5,"class":6},1]